In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Gamida Cell (GMDA - Research Report), with a price target of $17.00. The company's shares opened today at $3.07.According to TipRanks, Butler is an analyst with an average return of -2.8% and a 43.10% success rate. Butler covers the Healthcare sector, focusing on stocks such as Concert Pharma, Syros Pharmaceuticals, and Aquestive Therapeutics.Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $14.80, implying a 382.08% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $8.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-gamida-cell-gmda?utm_source=advfn.com&utm_medium=referral
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Gamida Cell Charts.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Gamida Cell Charts.